Low-dose abiraterone plus Olaparib as a late-line treatment for mCRPC patients without BRCA1/2 mutations: a multicenter retrospective pilot study

Low-dose abiraterone plus Olaparib as a late-line treatment for mCRPC patients without BRCA1/2 mutations: a multicenter retrospective pilot study

Abstract Although overall survival data are still premature, the PROpel study found radiological progression-free survival (PFS) benefits of abiraterone and olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC). However, for patients who have not been genetically tested o...

Full description

Bibliographic Details
Main Authors: Sijin Chen, Dewen Zhong, Chenbo Yu, Desheng Cai, Qichen Wei, Minggen Yang, Tao Li, Qingguo Zhu, Liefu Ye, Yongbao Wei, Jinfeng Wu
Format: Article
Language:English
Published: Nature Portfolio 2024-08-01
Series:Scientific Reports
Subjects:
Prostate cancer
Abiraterone
Olaparib
Late-line treatment
mCRPC
BRCA1/2 mutations
Online Access:https://doi.org/10.1038/s41598-024-70398-3

Internet

https://doi.org/10.1038/s41598-024-70398-3

Similar Items